Larimar Therapeutics
LRMR
59 hedge funds and large institutions have $124M invested in Larimar Therapeutics in 2022 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 18 increasing their positions, 7 reducing their positions, and 2 closing their positions.
950% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 2
339% more capital invested
Capital invested by funds: $28.2M → $124M (+$95.7M)
157% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 7
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
48% more funds holding
Funds holding: 40 → 59 (+19)
15.67% more ownership
Funds ownership: 81.27% → 96.94% (+16%)
96% less call options, than puts
Call options by funds: $2K | Put options by funds: $49K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$27.8M |
| 2 |
PA
Perceptive Advisors
New York
|
+$7.16M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$4.86M |
| 4 |
CA
CHI Advisors
New York
|
+$4.76M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.02M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$229K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$100K |
| 4 |
FFA
Fi3 Financial Advisors
Indianapolis,
Indiana
|
-$55.7K |
| 5 |
BlackRock
New York
|
-$13.4K |
LRMR Hedge Fund Activity: Q3 2022 in Review
59 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q3 2022, worth a combined $124M — up 339% from $28.2M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new LRMR positions and 2 closed out — a net gain of 19 holders — while 18 added to existing stakes and 7 trimmed.
The largest buyer was Deerfield Management, adding an estimated $27.8M. The largest seller was RA Capital Management, exiting entirely with an estimated $2.02M sold.
- 59 institutional investors held Larimar Therapeutics (LRMR) as of Q3 2022, up from 40 in Q2 2022.
- Funds reported $124M of Larimar Therapeutics stock for Q3 2022, up 339% quarter-over-quarter.
- 21 funds opened new Larimar Therapeutics positions in Q3 2022 and 2 closed out, a net change of +19 holders.
- The largest Larimar Therapeutics buyer in Q3 2022 was Deerfield Management, an estimated $27.8M added.
- The largest Larimar Therapeutics seller in Q3 2022 was RA Capital Management, an estimated $2.02M sold.
Based on aggregated 13F filings for Q3 2022.